<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in gastrointestinal (GI) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> including esophagus, gastric and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in GI tract and associated main adverse events </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:mp ids='MP_0001845'>inflammation</z:mp>, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels </plain></SENT>
<SENT sid="3" pm="."><plain>Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-inhibitory efficacy of non-selective <z:chebi fb="2" ids="35475">non-steroidal antiinflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential </plain></SENT>
<SENT sid="5" pm="."><plain>These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity </plain></SENT>
<SENT sid="6" pm="."><plain>The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors </plain></SENT>
<SENT sid="7" pm="."><plain>The efficacy and toxicity of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> are a consequence of the inhibition of the COX enzymes </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates </plain></SENT>
</text></document>